MiR-375 and Doxorubicin Co-delivered by Liposomes for Combination Therapy of Hepatocellular Carcinoma

• Main Authors: Yin-Ping Fan (Author), Jia-Zhi Liao (Author), Ya-Qi Lu (Author), De-An Tian (Author), Feng Ye (Author), Peng-Xuan Zhao (Author), Guang-Ya Xiang (Author), Wang-Xian Tang (Author), Xing-Xing He (Author)
• Format: Book
• Published: Elsevier, 2017-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Doxorubicin (DOX) is one of the most frequently used anti-cancer drugs and the front line option for hepatocellular carcinoma (HCC) treatment. However, the clinical applications of DOX are restricted largely due to its toxicity and chemoresistance. Here, we report that miR-375 and DOX were co-delive...